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Aim: To evaluate reasons for under-recruitment in an RCT of patients with severe mental
illness
Methods: Qualitative study during the recruitment phase of an RCT of supported employment.
Trial staff and recruiting clinicians were interviewed. Data were analyzed thematically using
constant comparative techniques.
Results: Recruitment rates were low. Five main reasons for recruitment difﬁculties were found.
These included: (i) misconceptions about trials, (ii) lack of equipoise, (iii) misunderstanding of
the trial arms, (iv) variable interpretations of eligibility criteria, (v) paternalism.
Conclusion: Reasons for recruitment difﬁculties in trials involving patients with severe mental
illness include issues that occur in trials in general, but others are more speciﬁc to these
patients. Clinician and patient involvement in the study design may improve recruitment in
future similar trials.
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Recruiting patients to randomised controlled trials (RCTs)
has long been recognized as a problem [1–3] with various
strategies developed to overcomebarriers to recruitment [4–7].
Recruitment delays can lead to increased costs accrued from
funding extensions or to reduced power of the study
[1,3]. Failure to recruit enough patients can result in early
closure of the trial, unanswered scientiﬁc questions and
wasted research resources. There may be particular difﬁcul-
ties in recruiting patients with severe mental illness into
RCTs due to concerns about their potential vulnerability and
reduced decision-making capacity [8]. However there is a).
Y license.lack of published research into whether patients with severe
mental illness are difﬁcult to recruit and why this may occur.
It is clearly important that this group is not excluded from
research. The aim of this paper was to evaluate reasons for
under-recruitment in an RCT of patients with severe mental
illness.
1.1. Method
This qualitative study was carried out during the recruit-
ment phase of the SWAN (Supported Work and Needs) trial.
The SWAN trial is an RCT of supported employment provided
by employment consultants integrated within community
mental health teams (CMHTs) with the aim of focusing on
rapid placement into jobs and continued follow-up support.
This intervention was compared with usual care which
consisted of existing psychosocial rehabilitation programmes
available in the local area. Unlike the intervention arm, the
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integrated into, the CMHTs.
Recruitment involved a two stage process. First, the care
coordinators (CCs) (mental healthcare professionals with a
background in nursing, social work or occupational therapy
who coordinate patient care and provide face to face care) in
CMHTs were asked to identify patients who fulﬁlled the
inclusion criteria for the SWAN trial (psychotic or chronic
affective disorder for over 2 years, age 18–65). The CCs ex-
plained the trial to these patients and asked their permission
to be contacted by a researcher. The researcher wrote to
patients inviting them to an appointment to further discuss
the trial. Enclosed with this invitation letter was a patient
information sheet. After meeting the potential participant
and explaining the trial, the research nurse (R) or trial
coordinator (TC) contacted the central randomization service
to arrange randomization for those patients who gave con-
sent to enter the trial. The trial coordinator and research nurse
were therefore responsible for liaisonwith CMHTs, discussing
potential subjects with CCs and recruiting patients after they
had been approached by CCs.
All staff of participating CMHTs were invited to attend
presentations from trial staff explaining the SWAN trial. These
presentations took place at the team base (communitymental
health centres) to maximise attendance. Information on the
trial was also provided in regular newsletters, advertisements
and printed summaries of the protocol. This included details
of local and national vocational agencies available for patients
randomised to the control arm. The recruitment period
started November 2004 and was originally planned to last
18 months. However, this was extended to 2 years because of
slow recruitment. The Quartet team was invited to explore
reasons for slow recruitment after the ﬁrst year of the trial
when 100 patients had entered the trial (the recruitment
target was 216 patients so the planned total after 1 year was
144).
2. Quartet methods
The Quartet (Qualitative research to improve recruitment
to randomised controlled trials) study works through colla-
boration with trial management groups to investigate
whether qualitative researchmethods can be used to improve
recruitment to RCTs experiencing or anticipating poor
recruitment. The Quartet study focuses on understanding
how the trial is presented to potential participants through-
out the recruitment process, providing evidence about
recruitment difﬁculties, and then, if possible, the develop-
ment of an intervention to improve recruitment, often
involving training or feedback to recruitment staff. The
research methods were developed from the ProtecT (Prostate
testing for cancer and Treatment) feasibility study [9] which
successfully increased randomization rates. Methods include
interviewing trial staff, either in groups or individually, and
recording and analyzing the eligibility and recruitment
appointments between health professionals and patients.
These methods are adapted for individual trials to unearth
barriers to recruitment. Data from interviews, focus groups
and appointments are transcribed and analysed using
techniques of constant comparison to identify important
themes.3. Collaboration with SWAN: data collection and
research methods
In collaboration with the SWAN trial, the Quartet team
decided to focus on interviews with trial and clinical staff and
not audio-recordings of recruitment appointments. This was
for two reasons. Firstly, the key recruitment stage was not the
recruitment appointment with the researcher — by which
time most patients had already decided to join the trial — but
when CCs ﬁrst introduced the trial to patients to see if they
agreed to be contacted by the researcher. This crucial
recruitment stage was difﬁcult to capture by audio-recording
as it occurred informally at any time and place as part of CCs'
clinical work. Secondly, the recruitment period did not allow
enough time for audio-recording and feedback.
The Quartet team initially interviewed four trial staff —
Chief Investigator (CI), Principal Investigator (PI), trial coordi-
nator (TC) and the research nurse (R) — followed by two CCs,
one ofwhomwas a teammanager. Interviews broadly covered
the recruitment process, perceived difﬁculties with the trial
and how it was run. They also focused on the acceptability of
trial arms, understanding of randomization andhoweligibility
was decided. After the interviews were transcribed, themes
arising from the datawere coded using ATLAS software. Codes
were compared across the data set and cross checked by two
independent researchers to ensure inconsistencies were
accounted for and to agree on signiﬁcant themes [10]. The
ﬁndings were then fed back to trial staff.
Following consultation with trial staff, the Quartet team
then led two workshops with two different teams of CCs,
based on the ﬁndings of the qualitative research. The original
aim of the workshops was for them to be an intervention to
feed back CCs' difﬁculties with the trial and to challenge
misconceptions and misunderstandings. However, practical
barriers, including governance procedures and reorganization
of teams delayed this, so that the workshops occurred near
the end of the recruitment period and their impact on
recruitment could not be evaluated.
The key issue of eligibility was explored in the workshops
through discussing four hypothetical scenarios of patients
whowere considered eligible for the trial by the PI. The aim of
these discussions was to ascertain whether CCs would refer
these patients as potential participants and whether there
was consensus on this. Two teams of CCs (out of 10) were
invited to participate in the workshops, based on their
expressed willingness and convenient locations. Out of
these two teams, seven CCs attended the ﬁrst workshop and
ten attended the second. Although only a relatively small
number of CCs and teams were represented, others were
included in the study through interviews, and the ﬁndings
were consistent. The workshops were organized so that trial
staff joined each group halfway through the session, allowing
CCs initial freedom to discuss the trial and later to ask
questions of trial staff.
4. Results
The aim throughout the collaboration was to understand
the reason for the low level of recruitment. Five key themes
emerged from the interviews and workshops reﬂecting views
about recruitment, and each is described in detail below.
Table 1
Misconceptions about RCTs
Extract 1
CC2: SWAN is still a study isn't it and it's still only ﬁfty ﬁfty and there was a
little bit of misrepresentation when they ﬁrst came out, because basically
ﬁfty percent of the guys were being told right no we can't do anything for
you, whereas you'd sort of let us, they let us sort of think that it was a sort of
grounded, established service to provide employment help… they said it was
a trial this that and the other but they certainly didn't say that you know
there's a good chance that your clients aren't going to get (the supported
employment). (Interview)
Extract 2
CC4: I referred three of my clients to these at the SWAN and I just got a letter
back saying that none of them had been taken on, but I didn't know why.
QR (Quartet researcher): You didn't know why, Ohh.
CC4: No I just got this letter back saying, “No, we've not taken them.” But I
would have liked to have known actually why.
QR: But do you understand now, why? From what I've said, that they were
randomised?
CC4: Yeah okay
QR: And the computer programmes, just by chance drew out the control arm
for them?
CC4: Yeah, okay (WS1)
Extract 3
CC7:With these random control trials, I had some clients, they were keen but
they don't know why they are getting put on the computer and were not
picked and then people that were not keen were being picked. So what am I
meant to do? (WS2)
Extract 4
CC8: It depends if she's robust enough to take the rejection if she doesn't get
into the trial I suppose. I suppose you would have to explain that to her that
she may not get in.
TS: What do you mean by get into the trial?
CC10: Well, into the intervention group I think she means. (WS1)
Extract 5
CC2: But then… it was really important that this guy got the support helping
him back to work that he needed. He got rejected, and it was a massive
blow, … really hit him hard ‘cos he wasn't, I don't think he was expecting it
either. (Interview)
Extract 6
CC5: I've got some written feedback from the client that went to SWAN,
which isn't positive because she felt that she told them everything about
herself, which was quite — she felt was quite personal and then she was told
that she wasn't given the service…. So it's sort of — she felt that she went
through quite a sort of process only to be said— told that no, you don't get the
service. (WS1)
Extract 7
R: I'd been explaining what randomisation was for the last year, and nobody
had understood it. And there's a temptation to think well, there's something
about me that's not explaining this right. And you know in fact, to have three
other people explaining it, (trial supervisor) had explained it, and you had
explained it, (Quartet member) had explained it, and still some of the same
questions were coming back (ﬁnal interview).
Table 2
Lack of equipoise
Extract 1
CC7: The intervention arm is better and the reason why I believe is that it
provides the extra support that the clients require to pass through the
selection and interview and help in gaining a job. Also the clients believe that,
apart from their employer, they have somebody that they can seek support
from because the SWAN shall make them aware if they have problems. And
also the third one (reason) which I am about to (say) is that the employer also
has prior knowledge about the individual, that if they are relapsing they can
inform the SWAN. (WS2)
Extract 2
CC2: I think basically you either get support or you don't. That's the way,
that's what it seems like at ground level
QR: Yeah, and support is a good thing?
CC2: Oh yeah
QR: Yeah, and do you think the trial's justiﬁed then?
CC2: No I don't think it's justiﬁed, it should be a service you know?
QR: Straightforward service?
CC2: Absolutely (Interview)
Extract 3
QR: Okay, do you ever have a personal feeling about which arm the patient
will do better in, when you actually get to see the patient?
R: Absolutely, yeah, I always want the intervention group (for them). And I
feel like I hate telling them they're in the control group, I absolutely hate it…
But yeah deﬁnitely I always will want the intervention group.
QR: Why is that?
R: I suppose because if they're expressing a need for work and they want
work and they want help in looking for a job then I want them to get that
help. (R: Interview)
Extract 4
QR: Your view of supported employment right at the beginning of the trial?
PI: Right at the beginning I thought it would probably help.
QR: So you were not in equipoise you thought that-?
PI: I was not in equipoise, but that was supported employment, the American
model. But it became increasingly clear that we weren't actually testing the
Americanmodel, so I hadmore equipoise as the studywent on, I would say yep.
(TS: Final Interview)
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CCs, who were very important in initially approaching
patients and introducing the study, held misconceptions
about randomised controlled trials (RCTs) despite being
familiar with the terms “trial” or “RCT”. Many CCs did not
realise SWAN was a study that randomly allocated patients to
either the control or intervention, and some had difﬁculty
with the role of randomization (Table 1). The CC in extract 1
had not understood his patients only had 50% chance of
getting the intervention, despite knowing it was a trial. In the
second extract, the CC did not realise that the trial had two
arms, that her patients had received the control arm, and thatthe process of randomization determined which arm a
patient received. In the third extract, a CC expressed difﬁculty
in explaining randomization to patients. In the fourth extract
the CC did not understand that getting the control arm was
the product of random selection, but saw it as rejection from
the trial.
These comments also reﬂected that patients and CCs
equated the intervention with the trial as a whole, a
misconception arising out of the trial name (Supported
Work And Needs — SWAN), so that the whole SWAN trial
was equated with the intervention. This confusion was
apparent in the way CCs described their patients' feelings
when receiving the control arm. As exempliﬁed in Table 1
(extracts 3, 4 and 5), not being included in the intervention
arm was commonly described in strong terms as “rejection”
or “a massive blow”. The experience of rejection expressed by
CCs and their patients went beyond feeling they had some-
how failed to be selected. They seemed to feel that patients
had been rejected despite needing and being suitable for
work (extract 5). The sixth extract reiterates these points that
the patient did not understand they were part of a trial and
that the trial was being confused with the intervention. This
conﬂation was possibly exacerbated by the lengthy baseline
interview (1–11/2 h) between the researcher and patient
before randomization.
Trial staff worked hard at communicating with the health
workers they relied on for the trial to work. There was regular
Table 3
Misunderstanding the trial arms
Extract 1
CC4: They were allocated out (control arm). I haven't done anything
QR: So you didn't refer them to another service then?
CC4: No…
QR: Because the idea behind the trial is that if your client gets allocated to the
control arm then they're not getting supported employment, and then there
is this list apparently of other options that you can use for them if they feel
that they still are interested in going for some kind of employment— for jobs—
and you didn't you know that?
CC5: No
CC6: No (lots of laughter), but we know now (laughs).
CC5: I meanwe haven't discussed it andwe didn't know that we had access to
these resources (WS1)
Extract 2
CI: Until the last year or so, the question of real openmarket paid employment
for people with more disabling conditions rarely came into the picture for
clinical teams…Not only was it not really often discussed or any action taken,
but rarely did the staff actually refer patients to this particular employment
agency.Which they could have done, but they didn't. So it wasn't as if this was
a sort of widely used option and it's a valuable resource and many people
going that way.…I think it's two things, one is the trial sensitised staff to the
question of work, but also that the wider health policy environment has
changed. (Interview)
Table 4
Interpreting eligibility
Extract 1
CC1:We have three zones, it's like the trafﬁc light system. Red obviously is for
clients who we're really concerned about who's not very well. Amber's for
clients who are fairly stable and ticking over quite well and the green zone is
for clients who have been maintaining wellness for quite sometime who we
feel would be able to move back into the community with support, but also
having the backup there just in case something was to go wrong. There are a
number of these clients who we refer on to SWAN, clients who we feel are
quite stable and would beneﬁt from a structure,… full time activity and
preparing them for employment… These are the green clients…the amber
ones we tend to wait until they're in the green bank…. Never the clients in
the red zone ‘cos obviously they're mentally not that well at the moment, at
that time, at that stage. (Interview)
Extract 2
CC7: I wouldn't refer them. I wouldn't refer them.
QR: Really, why?
CC11: I wouldn't.
CC12: I wouldn't.
QR: Why?
CC7:…So with someone like this you get them a job and within two or three
months they are relapsed, back in the hospital, the pressure is too much, it's
like they are not really well enough, because three months they are still
having a good and bad day, they are still complaining about their current
medication, they need to keep taking their medication.
CC3: But for me maybe the bad days are because she hasn't got anything to
do, nothing meaningful to do during the day. I would be more likely to refer
this lady because she is motivated, she is saying that she wants to go out…so
you have to take that on, she would like to go out to work. (WS 2)
Extract 3
CC8: I mean that all of our work is trying to sort of minimise (trigger factors)
and any change is going to enhance someone's stress and vulnerability aren't
they? So even trying something new even if it is positive, if she doesn't get on
it, it may increase her stress and vulnerability and she may start abusing
(drugs) again, so I suppose that would be your concern isn't it? I think if
things are stable, let's leave them as they are. Let's not add something into the
mix that might make her stressed again which might make her (relapse)
(WS1)
Extract 4
CC1: and a lot of people too, we've found is that they've not worked for a very
long time so the conﬁdence is not there, the self-esteem is quite low, the
motivation is not there at all so it's working on those self-esteem issues and
motivation issues and to get them to the point where they feel that they
would want to take that chance of going back out into mainstream and
ﬁnding some work, and there are some who feel overly ready but you know
yourself that they're not ready, it's those…that's where it's quite difﬁcult to
work it. (Interview)
Extract 5
QR: And are there certain people you deﬁnitely wouldn't (refer)?
CC2: Oh absolutely, I mean yeah another one of my guys, although this one in
particular is a very gifted craftsman, but you know his lifestyle, drugs and
chaotic lifestyle is just totally inappropriate to meet any sort of commitments
or take any responsibility even to getting up and you know, and attending
when you should, yeah ‘cos there's quite a few of our guys who are too
chaotic. (Interview)
Extract 6
CC1: For me deﬁnitely is that we don't know a lot of the clients that we've
recently inherited. So for us to be able to make referrals we need to get a
better understanding about the clients needs and I don't feel that we've
reached that stage yet. (Interview)
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and repeated explanations of the trial (extract 7). A list of
alternative vocational agencies for the control arm was
provided at the team presentations and enclosed in letters
to CCs whenever a patient was randomised to the control arm.
However, the CCs clearly still had misunderstandings about
the trial, could not ground it in their daily practice or make
sense of it to themselves or their clients. This was not helped
by the restructuring of the teams which led to changes inwho
was working within the CMHTs.
4.2. Equipoise
Expressing the control arm as rejection not only reﬂected
misconceptions about the trial but also a lack of equipoise
between the two arms. CCs did not accept that the control
arm was in any way equivalent to the intervention arm,
overwhelmingly favouring the intervention (Table 2). As CCs
assumed supported employment would be better for their
patients than usual care (extract 1), they were often
unsupportive of SWAN, considering the intervention should
be part of normal practice and not be tested in an RCT (extract
2). One CC exempliﬁed this attitude by describing the
intervention as a specialist service with the potential to
provide more than they themselves could offer (extract 3).
It was not only CCs who favoured the intervention arm
over the control arm; trial staff also expressed difﬁculty in
maintaining equipoise. Both the research nurse and PI
explained they considered the intervention arm to be more
successful in helping patients get work (extracts 4 and 5). Not
surprisingly, some patients randomised to the control arm
whowere disappointed with their allocation sought to obtain
the active intervention.
4.3. Misunderstanding the trial arms
A key problem for the trial was that CCs did not
understand the control arm of usual care and lackedinformation about how to present it. Although trial staff
referred to a list of possible alternative employment agencies
to which CCs could refer clients, some CCs had no knowledge
of this list (extract 1, Table 3). The Chief Investigator (CI)
considered that a major problem with the control arm was
that the notion of what constituted ‘usual care’was changing.
Whereas CCs may previously have not considered proper
Table 5
Paternalism: conﬂict in roles
Extract 1
CC8: So say people come with very complex issues about rejection and you
know this may feel like another rejection to them and we may have as
clinicians, we may feel we don't want to put our clients through that. (WS1)
Extract 2
CC3: I think thatmaybewe are a bit overprotective of the client group that we
work with because the majority of them have been through the system and
we tend to be at the latter end of the system, wherewe are trying to put them
into a situation where they feel good about themselves about going back to
work…
CC9: Plus we have a therapeutic rolewith the client and we are acutely aware
that the NHS is a huge and sort of mind boggling organisation for a lot of the
clients and they don't want to feel let down by the mental health system and
it's so easy for them to feel that way. (WS2)
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of the trial (extract 2, Table 3).
4.4. Eligibility
It became apparent in interviews that CCs had idiosyn-
cratic interpretations of who was eligible for the trial.
Furthermore, the way a patient's eligibly status was decided
varied from team to team. Whereas some CCs judged patients
individually, others reached consensus during teammeetings.
The approach of one team was to use a zoning system which
considerably reduced the pool of eligible patients (extract 1,
Table 4).
There was widespread fear among CCs that the stress of
inappropriate employment could trigger patients to relapse.
An exercise in the workshops was to discuss four potential
case scenarios, deemed eligible for the trial by the PI, and
explore whether CCs would refer them to the researcher. In
the ensuing debates several CCs stated that they would not
refer these patients to SWAN, a common reason being that the
stress of work would lead to their patients relapsing.
However, there was not necessarily consensus on this as
shown in the second and third extract. CCs used their own
perceptions of who was ready to work, not necessarily in
accordance with each other. This varied from being under
motivated due to low self-esteem or over motivated if not yet
“ready” for employment (extract 4). Some CCs deﬁned
patients who had chaotic lifestyles and could not take on
responsibility as unable to manage the intervention, giving
the impression that they made these decisions on behalf of
their patient (extract 5,). Finally, many teams were being re-
organised and taking over the care of unknown patients. CCs
felt that they could not discuss work with patients until they
had a clearer understanding of patients' needs irrespective of
whether or not they ﬁtted into the trial eligibility criteria
(extract 6).
4.5. Paternalism: conﬂict in roles
Both the issues of eligibility and equipoise reﬂected the
conﬂict between being a researcher recruiting for a trial and a
health professional protecting the interests of patients. Many
of the above extracts reveal that CCs primarily thought of
themselves as their patients' carers, focusing more on their
perception of patient needs than providing patients with the
opportunity to decide whether they would like to participate
in the research. As indicated above, CCs felt patients should be
protected from the stress of employment. Some patients were
also perceived as potentially too psychologically fragile to
deal with the consequences of being “rejected”, or allocated to
the control arm (extract 1, Table 5). The trial team described
the relationship between CCs and patients, where the health
professional decides on their patient's suitability for work, as
paternalistic. CCs acknowledged that they were a bit “over-
protective” of their patients (extract 2, Table 5).
4.6. Subsequent recruitment
As a result of these study ﬁndings, we subsequently
provided additional written and verbal information to teams,
and we were successful in exceeding our recruitment targetby the end of the second year (recruiting 219 patients to the
trial). However as the study was carried out relatively late in
the recruitment phase (partly because of delays in receiving
the relevant institutional approvals) it was not possible to
assess the impact of the intervention systematically.
5. Discussion
This study found ﬁve main reasons for recruitment
difﬁculties in this RCT. First, care coordinators (CCs), the
clinicians who initially approached patients and introduced
the study, did not appear to understand the concept of an RCT.
Second, they had difﬁculty in expressing equipoise. Third,
research and clinical staff had difﬁculty in accepting the usual
care arm, and patients did not always understand thedifference
between participation in the RCT and receiving routine care,
known as the “therapeutic misconception”. Fourth, CCs applied
their own eligibility criteria, not necessarily in accordance with
each other. Finally, they appeared paternalistic and focused
more on their perception of patient needs, such as avoiding the
stress of looking for a job or the psychological consequences of
the disappointment of being randomised to the control arm,
thanprovidingpatientswith theopportunity to decidewhether
they would like to participate in the research. These mis-
conceptions existed despite trial staff's efforts to provide on-
going support and address misunderstandings.
Some of these recruitment issues are known features of
RCTs in general whilst others are more speciﬁc to this
particular trial. It is known that clinicians involved in
recruiting to RCTs can have difﬁculties providing information
on key aspects of the research process, for example
randomization and equipoise [9,11–13]. This difﬁculty was
exacerbated in this trial by the fact that recruiting clinicians
had little interest in research and equated the intervention
with the trial. Lack of eligible patients is a major theme for
many trials [14] with clinicians employing their own inter-
pretations of the eligibility criteria [15,16]. Though it is
understandable that clinicians may want to interpret elig-
ibility criteria according to their own clinical experience, this
does have important implications for a trial if this differs from
the trial protocol and reduces and skews the pool of eligible
patients. Such practices can have a negative impact on
recruitment and affect the generalisability of results to a
clinical population [18]. In this trial the interpretation of who
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care managers adopted towards their patients.
A clear ﬁnding was the lack of individual equipoise —
deﬁned as genuine uncertainty about which trial arm is
better [17]. Usual care (treatment as usual — TAU) was
perceived by trial staff and patients as substandard in
comparison to the intervention arm; other researchers
have also reported that if a trial arm is perceived as less
desirable this can cause recruitment problems [18]. TAU as a
control arm is generally considered to be a reasonable and
ethically acceptable standard against which to measure the
effectiveness of a new treatment, and the bedrock of
pragmatic RCTs. In this trial TAU was provided by vocational
services delivered by providers outside the direct inﬂuence
of the trial. Care coordinators were confused about the
nature of TAU and could not properly describe it to their
patients. This was for two reasons. They considered the TAU
arm was effectively ‘no care’. In part this was because the
trial had sensitized them to the idea that competitive
employment could be beneﬁcial for their patients; conse-
quently vocational agencies that did not focus on competi-
tive employment for people with severe mental illness were
not considered as good. Second, they appeared confused
about what actually constituted TAU, partly because this did
not consist of a single understandable entity that provided
similar services everywhere.
If participants do not understand the purpose of a trial,
they may believe that the purpose of the trial discussion is to
provide the best individual care for them. This is known as the
therapeutic misconception. This can result in underestimat-
ing the risks or overestimating the beneﬁts of research
participation and thus hinder informed decision-making
[19]. In this trial patients and their clinicians felt let down
when they received the TAU arm, because they felt it implied
‘no care’. A number of authors have discussed the relevance of
the therapeutic misconception to the ethics of schizophrenia
research [19–21] but this phenomenon has also been
described in many non-psychiatric research populations
(e.g.[22–26]). Researchers have found that in patients with
schizophrenia or schizoaffective disorder, less education or
worse cognitive functioning is associatedwith higher levels of
therapeutic misconception [19]. This means that it would be
helpful that understanding is not assumed but checked when
working with this patient group.
Conﬂict in the roles of researcher and clinician is a
recognised problem for health professionals recruiting to
trials [3,15,27,28]. What is speciﬁc to this trial is the extent of
paternalism found between the clinicians and their patients,
reﬂecting the fact that the patient group are patients with
chronic mental illness and so perceived as especially vulner-
able. This has particular consequences for recruiting tomental
health trials. The recruiter–patient relationship is typically
long-term, with clinicians acting partly as their patients'
advocates. Although no one knows before a relapse how
much ‘stress’ will be bearable, the goal in such a therapeutic
context was often to avoid new challenges including those in
this trial: work or participating in research. CCs were also not
part of a research culture. The level of paternalism heremeant
that some, perhaps many, individuals were being denied
access to the trial and not allowed tomake an informed choice
about participating in the research.These ﬁndings are based on a small sample of intervie-
wees, which is a major limitation of this study. Information
was only disseminated directly to CCs who attended the
workshops, so any impact on recruitment processes would be
limited as non-attenders would not have received important
information. However, we subsequently also changed written
information to the CCs which was sent to all team members.
In addition, as with all retrospective studies, there is the
potential for recall bias, particularly as care coordinators and
researchers may have been looking for reasons for difﬁculties
in recruitment during interviews which took place in the
context of poor levels of recruitment. This study is also
speciﬁcally related to recruitment strategies that rely on
clinicians' indication, and other trials that do not rely on
clinicians (e.g. media advertisements, speciﬁc screening) are
likely to be associated with different recruitment issues.
Nevertheless, these ﬁndings may be relevant to trials with
similar recruitment procedures and highlight the need for
further research in this area. The ﬁndings also have practical
implications for future trials recruiting patients with severe
mental illness. Concern among research and clinical staff about
the vulnerability of research participants should be acknowl-
edged and discussed from the outset. Some researchers have
reported that impaired decision-making capacity can be
addressed by speciﬁc interventions [29–31] and such interven-
tions should be considered, particularly in patients with
cognitive impairment as this is themain predictor of incapacity
in this patient group. Recruiting clinicians also need to be very
clear on the reasons for the research, the eligibility criteria, the
role of randomization, theprocess of the studyand thenature of
the control arm. Usual care as the comparison needs to be
carefully explained and understood by those recruiting and
participating in the trial. These ﬁndings show that the Quartet
methods of listening to recruiters are essential in order to
understand the issues from their perspective. Presenting to and
talking to recruiters may not be enough.
It is perhaps understandable that recruitment is especially
difﬁcult when the process relies on clinicians who know little
about trials and donot have a career interest in research. For this
reason, clinician and patient involvement in study design may
prove vital in improving recruitmentandparticipation in similar
RCTs. It is clear in retrospect that if trial staff had initially elicited
and explored CCs' views about the rationale for the trial and
proposed recruitment practices they could have determined the
acceptability of these to those recruiting and their patients. Trial
staff need to recognize that health professionals may feel
ambivalent about research, especially if it appears of no beneﬁt
to themselves or their patients; addressing this may help
trialists overcome some recruitment hurdles in the future.
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